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Abstract
Background: The World Health Organization (WHO) End TB Strategy has established a milestone to reduce the
number of tuberculosis (TB)- affected households facing catastrophic costs to zero by 2020. The role of active case
finding (ACF) in reducing patient costs has not been determined globally. This study therefore aimed to compare
costs incurred by TB patients diagnosed through ACF and passive case finding (PCF), and to determine the
prevalence and intensity of patient-incurred catastrophic costs in Nepal.
Methods: The study was conducted in two districts of Nepal: Bardiya and Pyuthan (Province No. 5) between June
and August 2018. One hundred patients were included in this study in a 1:1 ratio (PCF: ACF, 25 consecutive ACF
and 25 consecutive PCF patients in each district). The WHO TB patient costing tool was applied to collect
information from patients or a member of their family regarding indirect and direct medical and non-medical costs.
Catastrophic costs were calculated based on the proportion of patients with total costs exceeding 20% of their
annual household income. The intensity of catastrophic costs was calculated using the positive overshoot method.
The chi-square and Wilcoxon-Mann-Whitney tests were used to compare proportions and costs. Meanwhile, the
Mantel Haenszel test was performed to assess the association between catastrophic costs and type of diagnosis.
Results: Ninety-nine patients were interviewed (50 ACF and 49 PCF). Patients diagnosed through ACF incurred
lower costs during the pre-treatment period (direct medical: USD 14 vs USD 32, P = 0.001; direct non-medical: USD
3 vs USD 10, P = 0.004; indirect, time loss: USD 4 vs USD 13, P < 0.001). The cost of the pre-treatment and intensive
phases combined was also lower for direct medical (USD 15 vs USD 34, P = 0.002) and non-medical (USD 30 vs
USD 54, P = 0.022) costs among ACF patients. The prevalence of catastrophic direct costs was lower for ACF
patients for all thresholds. A lower intensity of catastrophic costs was also documented for ACF patients, although
the difference was not statistically significant.
Conclusions: ACF can reduce patient-incurred costs substantially, contributing to the End TB Strategy target. Other
synergistic policies, such as social protection, will also need to be implemented to reduce catastrophic costs to zero
among TB-affected households.
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Background
The World Health Organization (WHO) End TB Strat-
egy has established a goal to end the global tuberculosis
(TB) epidemic. A key milestone to be achieved by 2020
is reducing the number of TB-affected households facing
catastrophic costs to zero [1]. A recent systematic review
including studies of sufficient quality with low risk of
bias conducted in Nigeria, Peru, China, and Moldova an-
alyzed the effect of cash interventions on treatment out-
comes. The review concluded that patients receiving a
TB-specific cash transfer were more likely to have a
positive clinical outcome than patients in the control
group (odds ratio [OR]: 1.77; 95% confidence interval
[CI]: 1.57–2.01) [2]. However, cash transfers alone are
unlikely to eliminate catastrophic costs. Active case find-
ing (ACF) has been recommended by international agen-
cies as a supportive strategy to reduce the financial
burden faced by TB patients [3, 4].
Studies have shown the importance of scaling up ACF
to eliminate the gap between estimated and notified TB
cases. The degree of case finding within national TB
programs varies globally and therefore ACF interven-
tions may encompass a range of strategies depending on
the underlying context. These can include: household or
social contact tracing, door-to-door screening, or tar-
geted screening of high-risk groups.
In Nepal, the implementation of ACF by the Birat
Nepal Medical Trust (BNMT) under the STOP TB/TB
REACH funding programme Wave 2 (ref) was con-
ducted in 15 Nepalese districts and detected 968 add-
itional cases in 18months (from January 2013 to June
2014) [5]. The ACF in Tuberculosis Trial (ACT2), which
analyzed the impact of ACF using a household contact
investigation of TB detection in Viet Nam, showed that
the implementation of ACF, in addition to strong passive
case finding (PCF), increased TB case detection from
703 per 100 000 population in the control districts to
1788 per 100 000 population in the intervention districts.
Intensive household contact tracing was also found to
reduce all-cause mortality in the intervention districts
from 1.7% (control districts) to 0.6% (intervention dis-
tricts; relative risk: 0.60; 95% CI: 0.50–0.80; P < 0.001)
[6]. The analysis found that household contact tracing is
a highly cost-effective intervention when compared with
PCF alone (USD 544 per disability-adjusted life year
averted) [7].
The implementation of ACF through TB REACH has
also dramatically increased the number of cases detected in
Ethiopia [8] and Cambodia, in the context of extremely
weak underlying national TB programs [9]. However, in-
creases in overall notification at the national level have not
been shown through these small-scale, short-term projects,
thus justification for national TB programs and global fun-
ders to invest in ACF remains weak. The Zambia South
Africa Tuberculosis and HIV/AIDS Reduction (ZAM-
STAR) cluster randomized trial of enhanced TB case find-
ing in the context of a high HIV prevalence failed to show
an impact on culture-confirmed TB prevalence after 4
years of intervention (OR = 1.09, 95% CI: 0.86–1.40) [10].
Furthermore, there is a lack of data to determine whether
ACF can reduce patient-incurred costs. The WHO has
been advocating strongly for research evidence from
diverse settings to inform policy development to achieve
the milestone of zero catastrophic costs [11].
In Nepal, the expansion of ACF is a key part of the
Strategic Interventions to Increase TB Case Notification
[12]. The National TB Programme (NTP) has planned to
expand ACF activities through the implementation of
community TB screening camps, screening of household
and social contacts of index TB patients, and scaling up
of GeneXpert® MTB/RIF testing (Xpert) [13]. Nepal has
continued to face challenges in crucial areas, such as a
sustained case detection gap, a poorly functioning health
system, and high dependence on international donor
funding for health (45% of the total budget) [14, 15].
Furthermore, a significant proportion of TB patients seek
care in the private sector due to weak public services [15],
increasing the risk of financial hardship for the most
vulnerable.
Previous cost and cost-effectiveness studies on TB con-
ducted in Nepal have evaluated patient-incurred costs
under either community-based or family member directly
observed treatment strategies, short-course (DOTS) for
TB control [16] and direct costs of outpatient visits to ob-
tain a TB diagnosis [17, 18]. This is the first study to
evaluate and compare patient costs incurred through a
diagnosis via ACF and PCF in the country. In a scenario
of scarce financial resources, health economic evaluations
play a key role in supporting the rational allocation of
resources and informing evidence-based policy develop-
ment. Therefore, the objective of this study was to com-
pare costs incurred by pulmonary TB patients diagnosed
through ACF and PCF, and determine the difference in
prevalence and intensity of catastrophic costs between
these groups.
Methods
Setting
Nepal is a low-income country with a population of 29
million people and a gross domestic product of USD 689
per capita [19]. In 2010, the poverty headcount ratio in-
dicated that 25% of the population was living below the
national poverty line [19]. In 2017, 31 764 cases of TB
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were notified by the NTP. The estimated TB incidence
rate was 152 cases per 100 000 inhabitants, giving a case
notification gap of more than 12 000 cases per year [14].
This TB patient cost study was conducted in two dis-
tricts of the BNMT TB REACH Wave 5 project in
Nepal, which aimed to increase case notifications of TB
through the implementation of ACF models (June 2017 –
December 2018). The BNMT TB REACH project was im-
plemented in eight districts, with four districts applying
Xpert for diagnosis (Pyuthan, Bardiya, Kapilvastu, and
Gulmi) and four districts using smear microscopy (Doti,
Achham, Argakhachi, and Salyan). The ACF model
adopted three strategic interventions to identify TB pa-
tients: (1) contact tracing of social contacts; (2) TB camps
for remote populations; and (3) screening at outpatient
departments (OPDs) of public hospitals (Additional files 2
and 3). Household contacts were not evaluated in this
TB REACH study because this was being carried out
in the project areas as part of The Global Fund activ-
ities of the NTP.
This TB patient cost survey was conducted in two dis-
tricts where the Xpert intervention was implemented:
Pyuthan and Bardiya, Province No. 5 (Additional file 4).
Pyuthan is a hilly district covering an area of 1309 km2
and has a population of 228 102 inhabitants [20]. It is
classified as a district with a medium TB burden by the
NTP, with 285 cases registered in 2017 [21]. Bardiya is a
lowland Terai district covering an area of 2025 km2 and
has a population of 426 576 inhabitants [20]. The district
is classified as having a high TB burden, with 601 cases
registered by the NTP in 2017 [21]. There is one govern-
ment hospital in each district. In Bardiya, there are 29
health posts and three primary healthcare centers. In
Pyuthan, there are 44 health posts and two primary health-
care centers. During the TB REACH project, 16 and seven
TB camps were held in Bardiya and Pyuthan districts,
respectively.
Study design and sampling
A cross-sectional study was conducted between June
and August 2018. As no data from Nepal were available
to inform a sample size determination, we set a sample
size based upon a previous cost survey (TB FIT: Filipino
Impact Assessment of new tuberculosis diagnostics)) [22],
which was sufficient to demonstrate an effect.
One hundred patients were included in this study in a
1:1 ratio (PCF:ACF, 25 consecutive ACF and 25 con-
secutive PCF patients in each district). ACF patients
who were between 2 weeks and 3 months into the inten-
sive phase of TB treatment were selected from a study
database of all patients diagnosed via ACF strategies.
PCF patients were identified from the treatment registers
at DOTS centers in each district. No eligible patients de-
clined participation.
Inclusion criteria
All adult (≥ 18 years) new and relapse TB cases regis-
tered in government facilities and who were residents of
Nepal were eligible for inclusion.
Case finding interventions
Three interventions were applied in the TB REACH pro-
ject. Details of the interventions are given in a paper
reporting the results of the ACF intervention (forthcom-
ing), and are described briefly below.
For the contact tracing intervention, a registered list of
TB patients (index patients) diagnosed between July 2016
and July 2017 was obtained from each government treat-
ment facility. Community Health Workers (CHWs) con-
tacted the index patients and interviewed them to identify
their social contacts. With the consent of the index
patient, identified social contacts were then contacted and
screened for signs and symptoms of TB using a simple
symptom questionnaire (presence of cough for more than
2 weeks, blood in cough, fever, night sweats, or weight
loss). Individuals reporting any of these symptoms were
then invited to provide a sputum sample for testing. The
CHWs collected the sputum sample in the morning and
delivered the sample for testing to the nearest diagnostic
facility. Those with a positive result received counseling
and were referred to initiate TB treatment at the nearest
health facility. Symptomatic individuals in more remote
areas of the district who tested negative by smear were
referred for Xpert testing at the district hospital. CHWs
followed up newly diagnosed TB patients to facilitate
treatment registration.
The second intervention was the establishment of TB
camps in high burden or remote areas of the districts to
screen, test with Xpert, and diagnose TB patients. CHWs
conducted door-to-door screening using the symptom
questionnaire 1 or 2 days prior to the camps being set up.
Patients diagnosed with TB were enrolled into treatment
by the CHWs at the nearest TB treatment center.
Symptomatic screening at the government district hos-
pitals’ OPDs was conducted among attendees using the
symptom questionnaire. Symptomatic individuals were
asked to provide a sputum sample for Xpert testing and
those with a positive diagnosis were enrolled into treatment
at the treatment center nearest to their place of residence.
Rifampicin-resistant cases were referred to multi-drug-
resistant (MDR) TB services.
Time horizon
Costs were collected at one point in time during the inten-
sive phase of treatment. The interviewers collected infor-
mation regarding costs incurred during the pre-treatment
period (that is, from the onset of the first reported TB
symptom until the first visit to a health facility for initiating
TB treatment) and during the intensive phase of treatment
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until the date of the interview. (that is, within 60 days of
treatment initiation for new cases and 90 days for relapse
cases). Costs incurred during the intensive phase were
extrapolated according to the number of remaining days of
treatment: costs incurred from treatment until the date of
interview x the proportion of the intensive phase to be
completed; for example, if a patient was interviewed on the
30th day (half of intensive phase completed for new cases),
the cost incurred until the day of the interview was multi-
plied by two (proportion of intensive phase to be com-
pleted = 60/30) [23].
Collecting data on costing
The WHO TB patient costing questionnaire was adapted
for this study. The questionnaire included questions on
clinical parameters; demographic variables; information
on employment and household composition; socioeco-
nomic position; healthcare utilization, including the num-
ber of visits and costs (direct medical and non-medical)
incurred during each visit in all types of health institu-
tions; time and income lost (indirect costs) while seeking
and receiving care; individual and family income; coping
mechanisms, such as loans taken, assets sold; and the fi-
nancial and social impacts of TB on patients and families.
The questionnaire was translated into Nepali and was
pre-tested on seven patients undergoing TB treatment in
Bardiya and Pyuthan. Minor corrections to the Nepali
version of the questionnaire were made following this
pilot testing. CHWs were trained in informed consent
procedures and to administer the interviews. They were
allocated to areas where they had relationships of trust
in the community. CHWs prepared a list of TB patients
diagnosed through ACF and PCF during the interven-
tion period and contacted them to schedule an interview
at their home or at the health facility. Those diagnosed
via household contract tracing in The Global Fund pro-
gram were not included in either group because the
study’s aim was to compare the TB REACH interven-
tions with passive patient presentation. Eligible individ-
uals were invited to participate, informed about the
purpose of the study orally and by a written patient in-
formation sheet (PIS), and were given an opportunity to
ask questions. The PIS was read to individuals with low
literacy levels. Written informed consent was obtained,
or a thumbprint for those unable to sign, following
standard Nepali practice. Compensation of 500 Nepalese
rupees (NPR) (approximately USD 4.5) was provided for
the time taken to complete the questionnaire (approxi-
mately 90 min).
Data completeness and consistency of information were
assessed after each interview and were cross-checked with
the patient treatment card. Data quality control was per-
formed by the district TB coordinators, a research associ-
ate, and the data manager.
Data entry and analysis
The WHO definition was applied to estimate the propor-
tion of TB-affected households experiencing catastrophic
costs: that is, the total costs (direct plus indirect) of seek-
ing TB diagnosis and care which exceeds 20% of the
annual household income [23]. We calculated the preva-
lence (that is, the proportion of patients with total costs >
20% of annual household income) and the intensity of
catastrophic costs (using the positive overshoot method;
that is, the average degree by which catastrophic costs
exceed the 20% threshold) [24] for each group. Income
loss, and individual and household income were self-
reported by patients. Time loss was also self-reported by
patients and converted to monetary values using the
human capital approach applying hourly and monthly
minimum wages of USD 0.62 and USD 4.67, respectively
[25]. Costs were collected in NPR and were converted to
USD applying the average exchange rate from OANDA
during the data collection period (NPR 1 =USD 0.00903)
(https://www1.oanda.com/) [26].
Data were entered by a trained technician into a be-
spoke web tool hosted by Koninklijke Nederlandse Cen-
trale Vereniging tot bestrijding der Tuberculose (KNCV)
TB Foundation and BNMT. Data analysis was performed
using Stata version 15 (StataCorp, College Station, Texas
77 845, USA). The mean imputation approach was used
to handle missing data and missing values were replaced
by the mean value of the costing items [27]. The patients
in each study arm were compared on socioeconomic
and clinical characteristics. The impact of ACF on costs
was determined by analyzing: (1) income changes and
social consequences of TB; (2) median costs per cost
component: that is, direct medical costs (drugs, tests,
consultation fees, hospitalization charges), non-medical
direct costs (transportation, food, accommodation), and
indirect costs (time and income loss); (3) median cost
per period of analysis (that is, the pre-treatment and in-
tensive phases); and (4) proportion of direct and indirect
costs per period of analysis.
The chi-square test was applied to test the difference in
proportions of categorical variables. The non-parametric
Wilcoxon-Mann-Whitney test was used to compare con-
tinuous variables (that is, costs). The Mantel-Haenszel ana-
lysis was performed to assess if the association between
catastrophic costs and type of diagnosis (ACF vs PCF) was
modified by other variables (gender, age, disease category,
poverty line, dissaving, financial and social impacts). Strati-
fied and pooled ORs and 95% CIs were reported together
with the P-value for the homogeneity test [28]. All P-values
below 0.05 were considered statistically significant.
A sensitivity analysis was performed to assess the im-
pact of varying the threshold for catastrophic costs (10,
20, 30, 40, 50, and 60%) on the prevalence of cata-
strophic costs for ACF and PCF patients. The prevalence
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of catastrophic costs was also calculated using only the
total direct costs as a proportion of the household an-
nual income.
The effect of recall bias was also assessed in both
groups. Median and interquartile costs were calculated
for ACF and PCF patients interviewed within 1 month
and after 1 month of treatment initiation.
Results
Patient characteristics
One hundred consecutively diagnosed TB patients were re-
cruited. One PCF patient with extrapulmonary TB was ex-
cluded, thus the final sample was 99 patients: 50 diagnosed
through ACF (three, 30, and 17 diagnosed via TB camps,
OPDs, and contact tracing, respectively) and 49 diagnosed
through PCF. All patients were interviewed during the in-
tensive phase, within 14 to 90 days of treatment initiation,
with 38% of patients interviewed during the first month of
treatment. All eligible patients invited to participate gave
written informed consent. Although MDR patients were
included in the eligibility criteria, there were no MDR TB
patients among those recruited. This is consistent with the
MDR TB prevalence of < 1% in these districts.
No differences in the socioeconomic characteristics
were found when comparing ACF and PCF patients (see
Table 1). The majority of patients were male (71%), con-
sistent with the 2:1 ratio of males and females in national
TB notification data. Twenty-five percent were aged over
65 years and 47% were farmers. The most common source
of drinking water was piped (49%) and the majority had a
standard toilet (latrine) in the home (74%). Electricity
(86%), a mobile phone (87%), and a bed (87%) were the
most frequent assets reported (see Table 1).
Disease and treatment characteristics
No differences were documented in disease characteristics
when comparing patients diagnosed by ACF or PCF. The
Table 1 Socio-economic characteristics of tuberculosis patients
diagnosed through active case finding (ACF) and passive case
finding (PCF), Nepal, 2018
Patient features ACF
N = 50
PCF
n = 49
All
n = 100
P-valuea
n (%) n (%) n (%)
Sex
Female 18 (36) 11 (22) 29 (29) 0.139
Male 32 (64) 38 (77) 70 (71)
Age group
15–24 7 (14) 5 (10) 12 (12) 0.367
25–34 3 (6) 10 (20) 13 (13)
35–44 9 (18) 8 (16) 17 (17)
45–54 10 (20) 8 (16) 18 (18)
55–64 10 (20) 6 (12) 16 (16)
65+ 11 (22) 12 (24) 23 (26)
Education statusb
No education or illiterate 14 (28) 18 (36) 32 (32) 0.536
Literate 12 (24) 8 (16) 20 (20)
Basic schools 20 (40) 16 (32) 36 (36)
Secondary schools 4 (8) 6 (12) 10 (10)
Master’s – 1 (2) 1 (1)
Occupation
Farmer 29 (58) 18 (36) 47 (47) 0.229
Homemaker 6 (12) 5 (10) 11 (11)
Others 15 (30) 26 (53) 41 (41)
Patient as main income earner
Yes 19 (38) 17 (34) 36 (36) 0.677
Source of drinking water
Piped 24 (48) 25 (50) 49 (49) 0.804
Well 1 (2) 2 (4) 3 (3)
Other 25 (50) 23 (46) 48 (48)
Toilet facilities
No toilets 4 (8) 3 (6) 7 (7) 0.936
latrine 36 (72) 38 (76) 74 (74)
Public sewage 4 (8) 3 (6) 7 (7)
Septic tank 6 (12) 5 (10) 11 (11)
Assetsc
Electricity 43 (86) 43 (86) 86 (86) 1
Radio 18 (36) 24 (48) 42 (42) 0.224
Mobile phone 42 (84) 45 (90) 87 (87) 0.372
Table 22 (44) 22 (44) 44 (44) 1
Chair 23 (46) 25 (50) 48 (48) 0.689
Bed 44 (88) 43 (86) 87 (87) 0.766
Cupboard 14 (28) 17 (34) 31 (31) 0.517
Clock 14 (28) 14 (28) 28 (28) 1
Fan 18 (36) 18 (36) 36 (36) 1
Table 1 Socio-economic characteristics of tuberculosis patients
diagnosed through active case finding (ACF) and passive case
finding (PCF), Nepal, 2018 (Continued)
Patient features ACF
N = 50
PCF
n = 49
All
n = 100
P-valuea
n (%) n (%) n (%)
Watch 20 (40) 22 (44) 42 (42) 0.685
Bicycle 22 (44) 18 (36) 40 (40) 0.414
Television 16 (32) 19 (38) 35 (35) 0.529
Livestock, small 37 (74) 40 (80) 77 (77) 0.476
Livestock, large 31 (62) 28 (56) 59 (59) 0.542
a Chi square
b Literate = able to only read and write, Basic schools = primary level/lower
secondary level (1 to 8 year of education)
c Other assets: refrigerator, ACF – 2 (4) and PCF - 4 (8); sofa, ACF - 1 (2) and
PCF - 2 (4); computer, ACF – 1 (2) and PCF – 2 (4); motorcycle, ACF 4 (8) - and
PCF – 2 (4); Animal-drawn cart, ACF – 5 (10), PCF 3 (6); thresher, ACF 1 (2)
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majority of patients were classified as new TB cases (83%)
and no patient reported a HIV positive status. A similar
proportion of both groups (ACF vs PCF) visited private
health services during the pre-treatment period (37% vs
41%) and sought diagnosis using public services (52% vs
54%). The average number of visits to health facilities dur-
ing the pre-treatment period (2.3 vs 2.6) and the average
number of follow-up visits after treatment initiation (0.2
vs 0.4) were lower among ACF patients. However, statis-
tical significance was reached only for follow-up visits
(P = 0.026). The average number of weeks between the
first symptom and treatment initiation was similar for
ACF and PCF patients (8.4 vs 8.8, P = 0.638) (see Table 2).
Income changes and social consequences
PCF patients reported a higher economic impact due to
TB treatment when compared with ACF patients, with
20% of PCF patients declaring being much poorer after
TB treatment initiation, while among ACF patients this
proportion was 2% (P = 0.016). TB resulted in a substan-
tial decrease in the individual and household incomes of
individuals diagnosed by either ACF or PCF. However, the
Table 2 Disease and treatment characteristics of tuberculosis patients diagnosed through active case finding (ACF) and passive case
finding (PCF), Nepal, 2018
Characteristics ACF
n = 50
PCF
n = 49
All
n = 100
P-value a
Treatment status n (%) n (%) n (%)
New 42 (84) 40 (82) 82 (82) 0.755
Retreatment/Relapse 8 (16) 9 (18) 17 (17)
HIV Status b
Not tested 8 (16) 4 (8) 12 (12) 0.485
Negative 39 (78) 40 (83) 79 (79)
Unknown 3 (6) 4 (8) 7 (7)
Number of patients with reported hospitalization
Pre-treatment 4 (8) 10 (20) 14 (14) 0.099
Intensive phase 0 1 (2) 1 (1) –
Total number of visits to health providers, pre-diagnosis c N = 114 N = 133 N = 247 –
Type of service visited, pre-diagnosis
TB camps 8 (7) 0 8 (3) 0.031
Cross border service d 0 1 (1) 1 (0.5)
Pharmacy/Herbalist 5 (4) 5 (4) 10 (4)
Private clinic/hospital 42 (37) 55 (41) 97 (39)
Public health facility 59 (52) 72 (54) 131 (53)
Total number of visits to health providers, intensive phase c N = 61 N = 64 N = 125 –
Type of service visited, intensive phase
No health facility 14 (23) 21 (33) 35 (28) 0.102
Private clinic/hospital 7 (11) 13 (20) 20 (16)
Public health facility 40 (66) 30 (47) 70 (56)
Average number of visits to health providers Mean (SD) Mean (SD) Mean (SD)
Health facility visits – pre-treatment 2.3 (1.1) 2.6 (1.6) 2.5 (1.4) 0.380
Health facility visits – intensive phase 0.9 (0.9) 0.9 (0.9)c 0.9 (0.9) 0.500
Follow-up visits - Intensive phase 0.2 (0.6) 0.4 (1.0) 0.3 (0.7) 0.026
Average number of days hospitalised
Pre-treatment 5.3 (3.8) 8.1 (7.0) 7.5 (6.4) 0.638
Average number of weeks between 1st
TB symptoms and treatment initiation
8.4 (8.0) 8.8 (11.3) 8.6 (9.8) 0.931
a Two-sample Wilcoxon rank-sum (Mann-Whitney) test and Chi square
b There is one missing data in HIV status
c Patients can have more than one visit to different health facilities
d Patient crossed the border to visit a health facility in India
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Table 3 Income changes and social consequences of tuberculosis in patients diagnosed through active case finding (ACF) and
passive case finding (PCF), Nepal, 2018
Item ACF
n = 50
PCF
n = 49
All
n = 100
P-value a
Income (USD) Mean (SD) Mean (SD) Mean (SD)
Individual income prior TB 79 (88) 70 (83) 80 (85) 0.602
Household income prior TB 196 (111) 182 (184) 189 (151) 0.052
Current individual incomeb 20 (44) 18 (37) 19 (40) 0.951
Current household incomeb 123 (101) 113 (174) 118 (142) 0.080
Working hours per week
Prior TB 31 (28) 29 (29) 30 (29) 0. 584
Currentb 5 (11) 4 (11) 4 (11) 0. 643
Catastrophic costs
Intensity c 61 (53) 88 (172) 76 (132) 0.6713
N (%) N (%) N (%)
Prevalence d 20 (45) 24 (61) 44 (53) 0.143
Employment status prior TB
Unemployed 2 (4) 5 (10) 7 (7) 0.475
Formal paid work 4 (8) 7 (14) 11 (11)
Informal paid work 24 (48) 17 (34) 41 (41)
Housework 15 (30) 13 (26) 28 (28)
Others 5 (10) 8 (16) 13 (13)
Current employment status b
Unemployed 13 (26) 18 (36) 31 (31) 0.310
Formal paid work – 2 (4) 2 (2)
Informal paid work 5 (10) 2 (4) 7 (7)
Housework 29 (58) 23 (46) 52 (52)
Others 3 (6) 5 (10) 8 (8)
Poverty headcount e
Before TB 5 (10) 6 (12) 11 (11) 0.749
Currentb 13 (26) 16 (32) 29 (29) 0.509
Dissaving strategies b
Loan 14 (28) 22 (44) 36 (36) 0.096
Sale of assets 4 (8) 5 (10) 9 (9) 0.727
Social impact b
Food insecurity 13 (26) 13 (26) 26 (26) 1
Loss job 2 (4) 4 (8) 6 (6) 0.400
Interrupted schooling 4 (8) 2 (4) 6 (6) 0.400
Social exclusion 10 (20) 7 (14) 17 (17) 0.424
Others 4 (8) 1 (2) 5 (5) 0.169
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higher impoverishment rate among PCF patients did not
appear to be a consequence of income reduction: there
was no difference in the income reduction between the
diagnostic groups, but rather time loss and out-of-pocket
expenses (further details below). The individual income
reduced by 75 and 74% for ACF and PCF patients, re-
spectively. The reduction in the household income was 37
and 38% for ACF and PCF patients, respectively. The pov-
erty headcount during the intensive treatment phase also
increased substantially in both diagnostic groups: 160 and
167% for individuals diagnosed by ACF or PCF, respect-
ively. A quarter of all patients (26%) reported food inse-
curity as a consequence of TB (see Table 3).
Costs
For the pre-treatment period, ACF patients reported
lower direct medical (USD 14 vs USD 32; P = 0.001),
non-medical (USD 3 vs USD 10; P = 0.004), and indirect
(USD 4 vs USD 13; P < 0.001) costs, the latter measured
using the human capital approach (that is, based on time
loss). The median total costs in this phase were also
lower for ACF patients, although not statistically signifi-
cant (USD 132 vs USD 172, P = 0.103) (see Table 4).
During the intensive treatment phase, ACF patients
also incurred lower direct non-medical (USD 0 vs USD
1), indirect (USD 55 vs USD 60), and total (USD 85 vs
USD 104) costs. However, statistical significance was
found only for direct non-medical costs (P = 0.034).
The median total cost (pre-treatment plus intensive
phase) was also lower for ACF patients, particularly for
direct medical (USD 15 vs USD 34, P = 0.002) and non-
medical (USD 30 vs USD 54, P = 0.022) costs. The total
direct costs were 65% lower for ACF patients compared
with PCF patients (USD 40 vs USD 115, P = 0.001) (see
Table 4).
Indirect costs, particularly income loss, were the main
driver of the total costs for both groups during the pre-
treatment and intensive phases. However, PCF patients
had higher percentages of direct medical (34% vs 10%)
and non-medical (9% vs 5%, P < 0.001) costs during the
pre-treatment period (see Fig. 1).
Catastrophic costs
Eighty-four patients were included in this analysis as 15
patients were unable to report the value of household in-
come. ACF patients presented 26% lower prevalence
(45% vs 61%) and 69% lower intensity (53% vs 172%) of
catastrophic costs, considering direct and indirect costs
(see Table 3).
Stratified analysis (Mantel-Haenszel) used to investi-
gate variables influencing the association of diagnostic
strategy with risk of catastrophic costs showed that
stratification by gender, TB relapse, poverty level, dissav-
ing, and financial and social impacts did not change the
OR of incurring catastrophic costs. However, stratifica-
tion by age revealed significant heterogeneity in the odds
of incurring catastrophic costs (P = 0.043), with those
aged under 60 years having an OR of 4.6 (95% CI: 1.19–
19.32) for catastrophic costs when diagnosed passively
rather than actively, compared to an OR of 0.6 (95% CI:
0.93–3.61) in those aged over 60 years (see Table 5).
Sensitivity analysis
The prevalence of catastrophic costs was higher for PCF
patients in all thresholds analyzed. Using the WHO
threshold (that is, 20% of annual household income) and
only direct costs, the prevalence of catastrophic costs
was 61% lower for ACF patients when compared with
PCF patients (13% vs 33%, P = 0.029) (see Fig. 2).
PCF patients were more strongly affected by recall bias
and lower costs were reported for patients interviewed
after 1 month of treatment initiation when compared with
those interviewed within 1 month of treatment initiation.
This suggests that in fact the PCF costs are more likely to
be underestimated and the effect of ACF on reducing pa-
tient incurred costs is in fact greater than estimated from
these self-reported data. PCF patients interviewed after 1
month of treatment reported lower indirect (USD 29 vs
USD 282, P < 0.001) and total (USD 128 vs USD 366, P =
0.007) costs during the pre-treatment period, than PCF pa-
tients patient interviewed greater than 30 days after treat-
ment initiation;. This difference was also seen for lower
direct non-medical (USD 16 vs USD 81, P = 0.005) and
Table 3 Income changes and social consequences of tuberculosis in patients diagnosed through active case finding (ACF) and
passive case finding (PCF), Nepal, 2018 (Continued)
Item ACF
n = 50
PCF
n = 49
All
n = 100
P-value a
Financial impactb
Much poorer 1 (2) 10 (20) 11 (11) 0.016
Poorer 26 (52) 22 (44) 48 (48)
Unchanged 23 (46) 18 (36) 41 (41)
a Chi square
b Intensive phase
c Intensity of catastrophic costs measured as median-positive overshoot beyond the 20% threshold
d Percentage of patients with total costs > 20% of annual family income (WHO)
e Number of families living with an annual income per capita below NPR 12000 (2011 prices) (http://www.thepovertyline.net/nepal
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Table 4 Median pre-treatment and treatment costs in tuberculosis patients diagnosed through active case finding (ACF) and
passive case finding (PCF), Nepal, 2018
Cost item ACF
(n = 50)
PCF
(n = 49)
Total
(n = 100)
P-valueb
Pre-treatment period Median (IQR) Median (IQR) Median (IQR)
Direct medical
Consultation fee 0.0 (0.0–0.1) 0.2 (0.0–4.5) 0.0 (0.0–1.0) 0.003
Radiography 0.5 (0.0–3.2) 3.2 (0.0–9.9) 1.6 (0.0–5.6) 0.003
Lab tests 1.1 (0.0–3.4) 2.7 (0.0–5.7) 1.8 (0.0–4.1) 0.092
Medicines 5.9 (0.0–16.8) 18.3 (1.5–36.7) 8.1 (0.5–25.6) 0.021
Other medical 0.0 (1.8–4.5) 3.3 (1.4–6.6) 2.7 (0.0–5.8) 0.013
Total direct medical 14.3 (4.5–27.7) 31.6 (11.0–79.1) 19.2 (6.3–46.3) 0.001
Direct non-medical
Transportation 3.3 (0.9–7.2) 5.4 (1.8–15.5) 3.7 (1.8–10.4) 0.031
Food – 0.0 (0.0–10.8) 0.0 (0.0–2.7) 0.006
Total direct non-medical 3.4 (1.8–10.4) 9.7 (2.7–37.9) 5.4 (2.1–22.4) 0.004
Indirect
Time lossa 4.4 (1.9–8.1) 13.4 (5.6–21.8) 7.8 (3.7–15.0) < 0.001
Income loss 51.4 (0.0–240.1) 30.7 (0.0–201.8) 40.6 (0.0–212.9) 0.629
Total indirect 63.5 (5.0–255.1) 43.3 (14.3–248.2) 51.1 (8.4–251.6) 0.430
Total cost pre-treatment 132.3 (22.6–258.0) 172.3 (59.9–405.4) 147.3 (41.6–304.9) 0.103
Intensive phase
Direct medical
Consultation fee/charges – – – –
Radiography/lab tests – – – –
Medicines – 0.0 (0.0–1.8) – 0.045
Total direct medical – 0.0 (0.0–4.0) – 0.070
Direct non-medical
Transportation 0.0 (0.0–7.2) 0.4 (0.0–17.3) 0.0 (0.0–8.5) 0.041
Food 0.0 (0.0–6.8) 0.0 (0.0–19.5) 0.0 (0.0–7.7) 0.547
Total direct non-medical 0.0 (0.0–14.4) 1.3 (0.0–44.8) 0.0 (0.0–28.0) 0.034
Indirect
Time lossa 29.9 (15.0–44.9) 31.0 (11.7–59.8) 29.9 (15.0–56.1) 0.816
Income loss 18.1 (0.0–49.7) 9.6 (0.0–45.2) 17.1 (0.0–45.2) 0.377
Total indirect 54.9 (29.9–95.9) 59.6 (34.9–82.7) 55.1 (29.9–90.5) 0.817
Other
Nutritional supplements 13.6 (7.5–25.4) 15.5 (9.3–35.3) 14.9 (8.1–27.8) 0.404
Total costs intensive phase 84.7 (56.1–144.0) 103.7 (45.3–193.2) 96.6 (51.8–176.9) 0.557
Total cost pre-treatment and intensive phase
Total direct medical costs 14.9 (4.5–46.1) 34.1 (13.1–87.5) 22.6 (6.7–63.8) 0.002
Total direct non-medical costs 29.6 (15.6–55.1) 54.0 (21.5–124.6) 37.5 (17.8–83.5) 0.022
Total direct costs 40.2 (26.1–91.7) 114.9 (45.3–250.5) 68.5 (31.7–148.6) 0.001
Total indirect costs 128.2 (34.9–357.4) 106.1 (57.8–340.9) 112.4 (52.4–343.7) 0.942
Total c 252.8 (80.9–452.8) 315.3 (125.8–543.9) 290.1 (88.7–476.7) 0.161
a Hourly minimum wage: USD 0.62; Daily minimum wage: USD 4.67 (http://www.pioneerlaw.com/news/minimum-wage-remuneration-2018–2075)
b Wilcoxon-Mann-Whitney
c Total cost: from the 1st TB symptoms until the end of intensive phase
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total (USD 68 vs USD 190, P = 0.004) costs during the in-
tensive phase; and lower indirect (USD 76 vs USD 367,
P = 0.003) and total (USD 232 vs USD 556, P = 0.002) costs
during both periods combined. There was no difference in
costs among ACF patients interviewed within and after 1
month of treatment initiation (see Table 6).
Discussion
This study demonstrated that patients diagnosed through
ACF incurred substantially lower costs than those diag-
nosed by PCF, with 65% lower direct costs and 61% lower
catastrophic cost prevalence when considering only direct
costs. The study also confirms the devastating financial
impact of TB on poor households in Nepal and the high
prevalence of catastrophic costs incurred by TB-affected
households in both groups, but particularly among pa-
tients diagnosed by PCF who are aged under 60 years.
Other costing surveys conducted in Asia have also
found lower costs and catastrophic costs among patients
diagnosed through ACF when compared with PCF. In
Cambodia, ACF patients incurred 79% lower total costs
during the pre-treatment period (USD 5 vs USD 24, P <
Fig. 1 The proportion of total costs attributed to each cost category (indirect, direct medical and direct non-medical) for patients diagnosed
by either ACF (right side of pie chart) or PCF (left side of pie chart). The median cost incurred for each category is also shown in USD.
Legend: P-value: Pearson’s chi-square test
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0.001, costs inflated to 2018 prices) [29]. In India, a TB
patient cost survey conducted in vulnerable populations
found 75% lower total costs (USD 5 vs USD 20, P <
0.001, 2018 prices) and 32% lower catastrophic costs
(adjusted prevalence ratio: 0.68, 95% CI: [0.69–0.97]) for
ACF patients [30].
The findings of this study indicate that ACF has the po-
tential to avert a substantial portion of direct costs and
catastrophic direct costs associated with TB diagnosis and
care, and can thereby help reduce the broader socioeco-
nomic consequences of TB in Nepal. Previous TB patient
cost surveys conducted among PCF patients in the coun-
try have found that high direct costs (that is, transporta-
tion, clinical fees, and tests) pose a barrier for patients
seeking TB diagnosis and treatment [17, 18]. In addition,
high costs have been associated with adverse TB outcomes
such as a delay in seeking diagnosis and starting treatment
[31, 32], death, and treatment abandonment or treatment
failure [33]. Thus, the implementation of ACF can poten-
tially contribute to improved treatment outcomes and re-
duce mortality [7]. These outcomes will be analyzed in an
ongoing project in Nepal (IMPACT TB).
The impact of ACF on direct costs, particularly during
the pre-treatment period, is principally a consequence of
savings incurred in transportation and diagnostic tests.
Nepal has a poor transport infrastructure, and many pa-
tients live in areas without roads and therefore have to
travel several hours or even several days to reach a health
service. ACF reduces or removes the need for patients to
travel long distances to reach diagnostic centers, or make
use of private health services, and pay for laboratory tests
or radiography. ACF patients receive visits from health-
care workers for TB screening, sputum collection, and fur-
ther referral for TB treatment for those with a positive
diagnosis. Besides decreasing patient costs, ACF increases
accessibility to health care.
Table 5 Association between catastrophic costs and passive case finding (PCF)/ active case finding (ACF) adjusted for each
exposure variable at time, Nepal, 2018
Variable Cases of catastrophic costs per diagnostic method n/N (%) a ORb (95% confidence interval) P-value c
PCF
N = 45
ACF
N = 39
Stratified Pooled
Total population 24/39 (61) 20/45 (44) 2 (0.77–5.25)
Variables
Gender
Male 20/31 (65) 14/28 (50) 1.8 (0.56–5.89) 1.8 (0.75–4.44) 0.993
Female 4/8 (50) 6/17 (35) 1.8 (0.24–13.84)
Age
< 60 20/25 (80) 14/30 (47) 4.6 (1.19–19.32) 2.1 (0.86–5.17) 0.043
≥ 60 4/14 (29) 6/15 (40) 0.6 (0.93–3.61)
Disease category
New case 19/33 (58) 17/38 (45) 1.7 (0.59–4.78) 2.0 (0.83–4.78) 0.330
Relapse 5/6 (83) 3/7 (43) 6.7 (0.34–392.48)
Poverty line
Bellow 4/5 (80) 5/8 (62) 2.4 (0.11–156.99) 2.1 (0.87–5.19) 0.924
Above 20/34 (58) 15/37 (40) 2.1 (0.73–6.03)
Dissaving
Yes 13/18 (72) 9/15 (60) 1.7 (0.32–9.60) 1.8 (0.75–4.49) 0.922
No 11/21 (52) 11/30 (37) 1.9 (0.53–6.84)
Financial impact
Poorer /Much poorer 15/22 (68) 14/26 (54) 1.8 (0.48–7.15) 2.1 (0.85–5.06) 0.758
Unchanged 9/17 (53) 6/19 (31) 2.4 (0.52–11.78)
Social impactd
Yes 10/14 (71) 14/23 (61) 1.6 (0.32–9.13) 2.5 (0.98–6.23) 0.437
No 14/25 (56) 6/22 (27) 3.4 (0.86–14.08)
a Five ACF and 11 PCF patients with “zero” annual family income excluded from this analysis
b Odds ratio (OR) was calculated using Mantel-Haenszel method
c P-value is from homogeneity test in Mantel-Haenszel analysis
d Social impact: divorce or social exclusion or food insecurity or loss of job or Interrupted schooling
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Other community-based initiatives covering different
areas of public health have been successful in improving
access to health care. China’s barefoot doctor system
(1968–1985) expanded the coverage of healthcare services,
reduced costs, and provided timely treatment by training
indigenous paramedics in rural areas of China [34]. In
Nepal, female CHVs have also improved access to health
care in urban and rural areas by delivering health promo-
tion and prevention activities at the household level [35].
Furthermore, village health workers, who were focused on
immunization programs, were promoted to auxiliary health
workers by the Ministry of Health in 2014–2015. The new
role was expanded to provide preventive and promotive
health services and basic curative services for the commu-
nity [35, 36].
A difference in total income loss was not identified in
this study, probably because the ACF strategy did not
appear to provide an earlier TB diagnosis. Earlier diagnosis
among patients diagnosed through ACF was identified in
previous studies in Cambodia [37] and Viet Nam [6], how-
ever, both studies evaluated ACF among household con-
tacts of index patients in addition to social contacts.
This study has a number of limitations. First, the cal-
culation of catastrophic costs considered self-reported
household income. This approach does not consider dis-
saving strategies and it is more challenging to apply in
countries with strong informal economies and seasonal
fluctuations in income, such as Nepal. However, the in-
terviewers were advised to ask about and explore the
average annual monthly income, regardless of seasonality
of the market. In addition, this approach has been widely
used [29, 30, 33, 38], which allows for comparisons to be
made between our findings and other studies. Second, the
calculation of catastrophic costs did not include costs in-
curred during the continuation phase of treatment, thus its
prevalence was underestimated. Third, the analysis did not
detect an association between key variables, such as pov-
erty line, social and financial impacts, dissaving strategies,
and the occurrence of catastrophic costs. A larger sample
size may be required to identify these associations. Fourth,
patients were recruited at different time points during the
intensive phase, which influenced the degree of recall bias
[39]. In this study, PCF patients were more affected by re-
call bias than ACF patients, and may have underestimated
their indirect, non-medical, and total costs as they were
interviewed 1 month after treatment initiation. Thus, as
these patients underestimated costs, the difference in costs
between ACF and PCF patients may be even higher.
The study also has a number of strengths. Interviews
were conducted by trained health workers who had a pre-
vious relationship with the community. The adoption of
this strategy was crucial to collect complete and accurate
data because a relationship of trust between interviewer
and participant is essential when asking sensitive ques-
tions about personal or household income. The present
study provides important evidence to inform policy evolu-
tion for ACF scale-up in Nepal. Knowledge of the compo-
nents, drivers, and distribution of costs for TB-affected
households will be necessary to develop and advocate for
effective interventions to mitigate costs and achieve the
End TB Strategy’s goal to reduce the number of TB-
affected households facing catastrophic costs to zero. Our
Fig. 2 Prevalence of catastrophic costs in tuberculosis patients diagnosed through active case finding (ACF) and passive case finding (PCF) during
the pre-treatment and intensive phases, Nepal, 2018
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Table 6 Median costs of patients interviewed within and after one month of treatment initiation, Nepal, 2018
Cost item Active case finding P-
valuea
Passive case finding P-
valuea
Total P-
valuea
< 1month
(n = 22)
> 1 month
(n = 28)
< 1 month
(n = 16)
> 1month
(n = 34)
< 1month
(n = 38)
> 1month
(n = 62)
Median (IQR) Median (IQR) Median (IQR) Median (IQR) Median (IQR) Median (IQR)
Pre-treatment
Direct medical 14.0 (0.0–27.7) 14.9 (6.3–31.7) 0.427 32.5 (8.6–80.7) 31.6 (14.3–79.1) 1 16.6 (4.3–46.1) 19.9 (9.6–46.5) 0.306
Direct non-medical 3.7 (2.7–7.2) 3.4 (1.4–12.1) 0.953 13.5 (2.3–49.3) 9.7 (2.7–35.2) 0.992 5.4 (2.7–21.7) 6.1 (2.0–22.6) 0.725
Indirect 51.0 (4.4–160.5) 68.1 (5.4–294.3) 0.814 281.8 (55.3–513.1) 28.8 (11.6–143.7) < 0.001 99.2 (6.3–408.4) 36.0 (8.7–194.3) 0.088
Total 121.8 (15.4–240.0) 146.7 (29.2–325.0) 0.639 365.9 (164.9–592.0) 128.5 (55.1–220.2) 0.007 121.8 (15.4–240.0) 146.7 (29.2–325.0) 0.237
Intensive phase
Direct medical 0 0 0.716 0 0 0.716 0 0 0.379
Direct non-medical 26.4 (14.1–45.9) 22.2 (8.4–37.0) 0.187 81.4 (33.8–141.8) 15.8 (6.5–38.6) 0.005 36.1 (18.1–78.0) 18.4 (8.1–37.8) 0.004
Indirect 51.5 (29.9–98.9) 54.9 (22.0–85.6) 0.494 63.5 (44.2–102.6) 54.2 (19.5–82.7) 0.126 58.8 (38.9–100.3) 54.9 (19.5–82.7) 0.128
Total 113.3 (56.4–144.0) 72.7 (46.1–133.6) 0.282 190.4 (113.2–234.5) 67.6 (39.3–143.4) 0.004 122.8 (72.1–193.2) 71.6 (41.1–143.4) 0.005
Total cost pre-treatment and intensive phase
Direct medical 14.9 (0.0–33.3) 14.9 (6.3–46.3) 0.617 40.3 (9.6–95.8) 33.5 (16.9–87.5) 0.934 24.9 (4.5–67.0) 21.1 (9.6–59.6) 0.477
Direct non-medical 33.2 (18.2–33.2) 28.0 (11.9–55.2) 0.369 102.2 (36.1–195.7) 30.8 (19.3–95.0) 0.061 48.9 (20.8–99.8) 30.0 (15.4–73.3) 0.113
Indirect 105.7 (34.9–313.8) 163.6 (38.2–394.8) 0.953 366.9 (97.2–628.9) 76.3 (50.9–246.9) 0.003 165.7 (82.8–538.8) 90.2 (46.1–308.3) 0.039
Total 209.3 (96.4–355.6) 280.5 (80.2–476.7) 0.815 556.3 (331.3–717.8) 232.3 (85.0–448.3) 0.002 337.5 (163.8–608.2) 244.4 (84.4–461.1) 0.091
a Chi square test
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findings indicate that ACF is an important strategy to con-
tribute to the achievement of this goal. A national TB pa-
tient cost survey for Nepal would provide comprehensive
data and should be prioritized. The impact of ACF on
catastrophic costs in other countries and population
groups should also be robustly evaluated to inform global
policy. Even though ACF reduced costs, the prevalence of
catastrophic costs was still found to be very high in both
groups. The expansion in coverage of social protection
would play an important role in alleviating extreme pov-
erty and, indirectly, in reducing TB incidence [40]. Cash
transfer programs, such as Bolsa FamÍlia in Brazil, have
been successful in reducing poverty and improving TB
treatment outcomes [41]. In Peru, socioeconomic support
for TB patients has improved TB outcomes and prevented
catastrophic costs [33, 42]. Similar interventions should be
piloted, evaluated, and integrated into the NTP in Nepal.
Conclusions
ACF is an important strategy to avert direct costs and to
reduce the proportion of TB households incurring cata-
strophic direct costs. Other policies, such as social pro-
tection, should be implemented in combination with
ACF to mitigate the financial burden of TB, particularly
among the most vulnerable populations.
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